Evidence map›Paper›PMID 42091792›Full record

ArticleDrug delivery and translational research2026

Intranasal lipid nanocapsule administration of the new lipophenol quercetin-3-O-DHA-7-O-iPr reduces carbonyl stress and improves behavior in a mouse model of Alzheimer's disease.

Léa Otaegui, Jordan Lehoux, Sylvie Begu, Tristan Moujellil-Legagneur, Charleine Zussy, Mathieu Vitalis, Magalie Mathias, Annaëlle Beau, Thierry Durand, Laurent Givalois and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Léa OtaeguiMMDN, University of Montpellier, EPHE, INSERM, Montpellier, France.
Jordan LehouxPôle Chimie Balard Recherche, IBMM, University of Montpellier, CNRS, ENSCM, Montpellier, 34293, France.
Sylvie BeguICGM, University of Montpellier, CNRS, ENSCM, Montpellier, France.
Tristan Moujellil-LegagneurMMDN, University of Montpellier, EPHE, INSERM, Montpellier, France.
Charleine ZussyMMDN, University of Montpellier, EPHE, INSERM, Montpellier, France.
Mathieu VitalisMMDN, University of Montpellier, EPHE, INSERM, Montpellier, France.
Magalie MathiasMMDN, University of Montpellier, EPHE, INSERM, Montpellier, France.
Annaëlle BeauMMDN, University of Montpellier, EPHE, INSERM, Montpellier, France.
Thierry DurandPôle Chimie Balard Recherche, IBMM, University of Montpellier, CNRS, ENSCM, Montpellier, 34293, France.
Laurent GivaloisMMDN, University of Montpellier, EPHE, INSERM, Montpellier, France.
Nathalie Bernoud-HubacUniversity of Lyon, INSA Lyon, CNRS, LAMCOS, Villeurbanne, UMR5259, 69621, France.
Céline CraustePôle Chimie Balard Recherche, IBMM, University of Montpellier, CNRS, ENSCM, Montpellier, 34293, France.
Catherine DesrumauxMMDN, University of Montpellier, EPHE, INSERM, Montpellier, France. catherine.desrumaux-piazza@umontpellier.fr.

Funding

Agence Nationale de la Recherche ANR-11-LABEX-0021-LipSTICAgence Nationale de la Recherche ANR-18-CE18-0017Agence Nationale de la Recherche ANR-AAP2022-R22102FF-EpiNeurAgeAssociation France Alzheimer PhD grantFondation pour la Recherche Médicale MND202003011477-OPAUniversité Montpellier CBS2 PhD grantUniversité Montpellier MUSE-AAP20REC-FRS09-GAiA
6 · The paper itself

Abstract

Oxidative and carbonyl stresses (COS), which damage brain cells through the accumulation of toxic reactive carbonyl species (RCS), are key players in the etiology of Alzheimer's disease (AD). Our group developed lipophenols, i.e. COS-targeting hybrid molecules combining polyunsaturated fatty acids (PUFAs) and alkyl-(poly)phenols. Among them, quercetin-3-O-docosahexaenoate-7-O-isopropyl (Quercetin-3-O-DHA-7-O-iPr or "Q-iP-DHA") afforded neuroprotection against acrolein-induced toxicity, reduced carbonyl stress, and lowered amyloid-beta secretion in neuroblastoma cells. To evaluate Q-iP-DHA in vivo, it was formulated into lipid nanocapsules (to allow solubilization) then administered intranasally to J20 transgenic mice, a model of AD. This approach was chosen to optimize blood-brain barrier (BBB) penetration. This delivery led to improvements in well-being, organizational skills and spatial memory. In addition, Q-iP-DHA treatment reduced hippocampal amyloid plaque numbers, normalized expression of the Receptor for Advanced Glycation End-products (RAGE), and decreased microglial activation, indicating anti-inflammatory effects. Overall, our preclinical findings suggest that intranasal administration of nanoformulated Q-iP-DHA may represent a promising multitarget therapeutic approach against AD.

Identifiers

PMID42091792

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.